DrugPatentWatch Database Preview
Litigation Details for Cadence Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2013)
Cadence Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2013)
| Docket | Start Trial | Date Filed | 2013-01-18 |
| Court | District Court, N.D. Illinois | Date Terminated | 2013-03-12 |
| Cause | 28:1331 Federal Question | Assigned To | Gary Scott Feinerman |
| Jury Demand | None | Referred To | |
| Parties | CADENCE PHARMACEUTICALS, INC.; FRESENIUS KABI USA, LLC; SCR PHARMATOP | ||
| Patents | 6,028,222; 6,992,218 | ||
| Attorneys | Adam T Waskowski; Andrew Dylan Campbell; Kenneth G. Schuler; Marc N. Zubick; Stephen R. Buckingham | ||
| Firms | Latham & Watkins LLP; Latham and Watkins LLP; Lowenstein Sandler; Novack and MacEy, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Cadence Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC
The small molecule drug covered by the patents cited in this case is Start Trial .
Details for Cadence Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2013)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2013-01-18 | 1 | United States Patent No. 6,028,222 and U.S. Patent No. 6,992,218 (collectively, the “Patents-in-Suit”). … THE PATENTS-IN-SUIT 10. United States Patent No. 6,028,222 (“the ’222 patent”), titled… the ’222 patent. 11. Pharmatop granted an exclusive license to the ’222 patent to Bristol-Myers…copy of the ’222 patent is attached as Exhibit A. 12. United States Patent No. 6,992,218 (“… the ’218 patent. 13. Pharmatop granted an exclusive license to the ’218 patent to BMS, with | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
